Check Out What Whales Are Doing With VRTX

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 9 unusual trades.

Delving into the details, we found 33% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $182,000, and 7 were calls, valued at $518,535.

Latest Startup Investment Opportunities:

Projected Price Targets

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $350.0 to $450.0 for Vertex Pharmaceuticals during the past quarter.

Insights into Volume & Open Interest

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Vertex Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Vertex Pharmaceuticals's significant trades, within a strike price range of $350.0 to $450.0, over the past month.

Vertex Pharmaceuticals Call and Put Volume: 30-Day Overview

Significant Options Trades Detected:

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

After a thorough review of the options trading surrounding Vertex Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Where Is Vertex Pharmaceuticals Standing Right Now?

• With a volume of 597,514, the price of VRTX is down -2.66% at $434.2.
• RSI indicators hint that the underlying stock may be approaching overbought.
• Next earnings are expected to be released in 5 days.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.